High-throughput screening to identify compounds that increase fragile x mental retardation protein expression in neural stem cells differentiated from fragile x syndrome patient-derived induced pluripotent stem cells

Stem Cells Translational Medicine

Volumn 4, Issue 7, 2015, Pages 800-808

  Kumari, Daman ^a   Swaroop, Manju ^b   Southall, Noel ^b   Huang, Wenwei ^b   Zheng, Wei ^b   Usdin, Karen ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Fibroblasts; Fragile X mental retardation protein assay; Fragile X syndrome; High throughput screening; Induced pluripotent stem cells; Neural stem cells

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN;

ARTICLE; CONTROLLED STUDY; FLUORESCENCE RESONANCE ENERGY TRANSFER; FRAGILE X SYNDROME; GENE ACTIVATION; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NEURAL STEM CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

EID: 84936996242     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0278     Document Type: Article

References (42)

1. Goldson E, Hagerman RJ. The fragile X syndrome. DevMed Child Neurol 1992; 34: 826-832.
2. Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X: Leading the way for targeted treatments in autism. Neurotherapeutics 2010; 7: 264-274.
3. Fu YH, Kuhl DP, Pizzuti A et al. Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. Cell 1991; 67: 1047-1058.
4. Verkerk AJ, Pieretti M, Sutcliffe JS et al. Identification of a gene (FMR-1) containing aCGGrepeatcoincidentwithabreakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65: 905-914.
5. Coffee B, Zhang F, Ceman S et al. Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile X syndrome. Am J Hum Genet 2002; 71: 923-932.
6. Sutcliffe JS, Nelson DL, Zhang F et al. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet 1992; 1: 397-400.
7. Ascano M Jr., Mukherjee N, Bandaru P et al. FMRPtargets distinctmRNAsequence elements to regulate protein expression. Nature 2012; 492: 382-386.
8. Brown V, Jin P, Ceman S et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2001; 107: 477-487.
9. Darnell JC, Van Driesche SJ, Zhang C et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011; 146: 247-261.
10. Eberhart DE, Malter HE, Feng Y et al. The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet 1996; 5: 1083-1091.
11. Lee EK, Kim HH, Kuwano Y et al. hnRNP C promotes APP translation by competing with FMRP for APP mRNA recruitment to P bodies. Nat Struct Mol Biol 2010; 17: 732-739.
12. JeonSJ, Seo JE, Yang SI etal. Cellular stressinduced up-regulation of FMRP promotes cell survival bymodulating PI3K-Akt phosphorylation cascades. J Biomed Sci 2011; 18: 17.
13. Luća R, Averna M, Zalfa F et al. The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation. EMBO Mol Med 2013; 5: 1523-1536.
14. Alpatov R, Lesch BJ, Nakamoto-Kinoshita Met al. Achromatin-dependent role of the fragile X mental retardation protein FMRP in the DNAdamage response. Cell 2014; 157: 869-881.
15. Zhang W, Cheng Y, Li Y et al. A feedforward mechanism involving Drosophila fragile X mental retardation protein triggers a replication stress-induced DNA damage response. Hum Mol Genet 2014; 23: 5188-5196.
16. Feng Y, Gutekunst CA, Eberhart DE et al. Fragile X mental retardation protein: Nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci 1997; 17: 1539-1547.
17. Darnell JC, Klann E. The translation of translational control by FMRP: Therapeutic targets for FXS. Nat Neurosci 2013; 16: 1530-1536.
18. Hagerman RJ, Hull CE, Safanda JF et al. High functioning fragile X males: Demonstration of an unmethylated fully expanded FMR-1. mutation associated with protein expression. Am J Med Genet 1994; 51: 298-308.
19. Guo W, Allan AM, Zong R et al. Ablation of FMRP in adult neural stem cells disrupts hippocampus-dependent learning. Nat Med 2011; 17: 559-565.
20. Chiurazzi P, Pomponi MG, Willemsen R et al. In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum Mol Genet 1998; 7: 109-113.
21. Biacsi R, Kumari D, Usdin K. SIRT1 inhibition alleviates gene silencing in fragile X mental retardation syndrome. PLoS Genet 2008; 4: e1000017.
22. Hagerman P. Fragile X-associated tremor/ataxia syndrome (FXTAS): Pathology and mechanisms. Acta Neuropathol 2013; 126: 1-19.
23. Allen EG, Sullivan AK, Marcus M et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod 2007; 22: 2142-2152.
24. Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000; 97: 189-194.
25. Wittenberger MD, Hagerman RJ, Sherman SL et al. The FMR1 premutation and reproduction. Fertil Steril 2007; 87: 456-465.
26. Jin P, Duan R, Qurashi A et al. Pur alpha binds to rCGG repeats and modulates repeatmediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron 2007; 55: 556-564.
27. Sellier C, Freyermuth F, Tabet R et al. Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Reports 2013; 3: 869-880.
28. Sellier C, Rau F, Liu Y et al. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J 2010; 29: 1248-1261.
29. Todd PK, OhSY, KransAet al. CGGrepeatassociated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron 2013; 78: 440-455.
30. Kenneson A, Zhang F, Hagedorn CH et al. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet 2001; 10: 1449-1454.
31. Tassone F, Hagerman RJ, Iklé DN et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am J Med Genet 1999; 84: 250-261.
32. Huang R, Southall N, Wang Y et al. The NCGC pharmaceutical collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 2011; 3: 80ps16.
33. Southall N, Jadhav A, Huang R et al. Enabling the large scale analysis of quantitative high throughput screening dataHandbook of Drug Screening. In: Seethala R, Zhang L, eds2nd ed. New York: Taylor & Francis, 2009442-463.
34. Schutzius G, Bleckmann D, Kapps-Fouthier S et al. A quantitative homogeneous assay for fragile X mental retardation 1 protein. J Neurodev Disord 2013; 5: 8.
35. GuoW, MurthyAC, Zhang L et al. Inhibition of GSK3b improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum Mol Genet 2012; 21: 681-691.
36. Chen X, Sun W, Pan Y et al. Lithium ameliorates open-field and elevated plus maze behaviors, and brain phospho-glycogen synthase kinase 3-beta expression in fragile X syndrome model mice. Neurosciences (Riyadh) 2013; 18: 356-362.
37. Liu ZH, Chuang DM, Smith CB. Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol 2011; 14: 618-630.
38. Ignarro LJ, Wood KS, Wolin MS. Activation of purified soluble guanylate cyclase by protoporphyrin IX. Proc Natl Acad Sci USA 1982; 79: 2870-2873.
39. Fulton SC, Healy MD. Comparison of the effectiveness of deserpidine, reserpine, and alpha-methyltyrosine on brain biogenic amines. Fed Proc 1976; 35: 2558-2562.
40. Arora SK. Molecular structure of heliomycin, an inhibitor of RNA synthesis. J Antibiot (Tokyo) 1985; 38: 113-115.
41. Hase J, Kobashi K, Kawaguchi N et al. Antimicrobial activity of hydroxamic acids. Chem Pharm Bull (Tokyo) 1971; 19: 363-368.
42. Odake S, Morikawa T, Tsuchiya M et al. Inhibition of Helicobacter pylori urease activity by hydroxamic acid derivatives. Biol Pharm Bull 1994; 17: 1329-1332.